Advertisement

Pharmaceutical Chemistry Journal

, Volume 45, Issue 12, pp 754–756 | Cite as

Determining Niferidil in Blood Serum Using Reversed-Phase High-Performance Liquid Chromatography

  • S. M. Filimonova
  • N. S. Bogomolova
  • V. V. Chistyakov
STRUCTURE OF CHEMICAL COMPOUNDS, METHODS OF ANALYSIS AND PROCESS CONTROL
  • 37 Downloads

A reversed-phase high-performance liquid chromatography (RP-HPLC) technique is described that can be used for the determination of niferidil in rat blood serum. The RP-HPLC procedure is carried out on a Silasorb SF C8 column (150 × 4 mm, 5 μm) eluted with a MeOH:H2 O (45:55) mobile phase (adjusted to pH 2.5 with orthophosphoric acid and then to pH 3.5 with propylamine) at a flow rate of 1 mL/min with UV detection at 265 nm. The procedure is as follows: mix rat blood serum (1 mL), NaHCO3 solution (100 μL), and CHCl3 (3 mL) in a 10-mL glass centrifuge tube. Shake for 2 min and centrifuge at 3,000 rpm for 10 min. Transfer the CHCl3 phase into another tube and evaporate to dryness under a stream of nitrogen. Reconstitute the residue in mobile phase (100 μL) and inject an aliquot (20 μL) into the chromatographic column. The average recovery of niferidil is 70%. The detection limit is 0.01 μg/mL. The method was linear from 0.02 to 0.5 μg/mL with a correlation coefficient of 0.968. The coefficient of variation was less than 12% within a day (n = 5). The proposed method was successfully used to determine some pharmacokinetic parameters after intravenous injection of niferidil in rats.

Keywords

antiarrhymthic drug niferidil RP-HPLC blood serum quantitative analysis 

References

  1. 1.
    B. N. Singh and K. Nademanee, Am. Heart J., 109(2), 421 – 430 (1985).PubMedCrossRefGoogle Scholar
  2. 2.
    B. N. Singh, Eur. Heart J., 14 (Suppl. H), 14 – 23 (1993).PubMedGoogle Scholar
  3. 3.
    K. A. Ellenbogen, B. S. Stambler, M. A. Wood, et al., J. Am. Coll. Cardiol., 28(1), 130 – 136 (1996).PubMedCrossRefGoogle Scholar
  4. 4.
    A. Capucci and D. Aschieri, Eur. Heart J., 5 (Suppl. H), 8 – 18 (2003).Google Scholar
  5. 5.
    I. I. Miroshnichenko, I. I. Tyulyaev, and A. P. Zuev, Bioavailablity of Drugs [in Russian], Gramotei, Moscow (2003), pp. 26, 27.Google Scholar
  6. 6.
    N. A. Epshtein, Khim.-farm. Zh., 38(4), 44 – 46 (2004).Google Scholar
  7. 7.
    F. Bressole, M. Bromet-Petit, and M. Audran, J. Chromatogr. B: Biomed. Sci. Appl., 686, 3 – 10 (1996).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2012

Authors and Affiliations

  • S. M. Filimonova
    • 1
  • N. S. Bogomolova
    • 1
  • V. V. Chistyakov
    • 1
  1. 1.Center for Drug Chemistry, All-Russia Research Institute of Pharmaceutical ChemistryMoscowRussia

Personalised recommendations